• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure
J Clin Endocrinol Metab. 2023 Jul 6:dgad398. doi: 10.1210/clinem/dgad398. Online ahead of print.ABSTRACTGlucagon-like peptide-1 receptor agonists (GLP-1 RA) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RA may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across patient's risk with a particular focus in HF. After a careful review of the literature, we challenge the c...
Source: The Journal of Clinical Endocrinology and Metabolism - July 6, 2023 Category: Endocrinology Authors: Jo ão Pedro Ferreira Abhinav Sharma Javed Butler Milton Packer Faiez Zannad Francisco Vasques-N óvoa Adelino Leite-Moreira Jo ão Sérgio Neves Source Type: research

Testosterone replacement therapy in relation with cardiovascular disease in cisgender women and transgender people
CONCLUSION: Use of TTh increased the risk of CVD, CAD and stroke among is cisgender women, but not among transgender people. TTh is becoming more widely accepted in women, and it is the main medical treatment for transgender males. Therefore, use of TTh should be further investigated for the prevention of CVD.PMID:37392459 | DOI:10.1210/clinem/dgad388
Source: The Journal of Clinical Endocrinology and Metabolism - July 1, 2023 Category: Endocrinology Authors: David S Lopez Juwairia S Mulla Danielle El Haddad Md Ibrahim Tahashilder Efstathia Polychronopolou Jacques Baillargeon Yong-Fang Kuo Syed Gilani Wissam I Khalife Source Type: research

Associations of Serum 25(OH)D with Risk of Recurrent Cardiovascular Events in Individuals with Coronary Heart Disease
This study aimed to investigate the associations of serum 25-hydroxyvitamin D [25(OH)D] concentration and the vitamin D receptor (VDR) polymorphisms with the risk of recurrent cardiovascular events in individuals with established CHD.METHODS: A total of 22,571 participants with CHD were included from the UK Biobank. Recurrent cardiovascular events, including myocardial infarction (MI), heart failure (HF), stroke, and CVD mortality, were identified from electronic health records. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).RESULTS: The median (interquartile ra...
Source: The Journal of Clinical Endocrinology and Metabolism - June 6, 2023 Category: Endocrinology Authors: Xiaoyu Lin Xue Chen Sen Liu Yulei Deng Yuexuan Wang Qi Lu Rui Li Yunjing Ou Qingying Tian Yunfei Liao Guanglin Cui Kun Yang An Pan Gang Liu Source Type: research

Cardio-cerebrovascular Outcomes in MODY, Type 1 Diabetes, and Type 2 Diabetes: A Prospective Cohort Study
CONCLUSIONS: MODY diagnosed by genetic analysis represents higher prevalence than the clinical diagnosis in UK Biobank. The risk of incident cardio-cerebrovascular events in MODY ranks between type 1 diabetes and type 2 diabetes.PMID:37093977 | DOI:10.1210/clinem/dgad233
Source: The Journal of Clinical Endocrinology and Metabolism - April 24, 2023 Category: Endocrinology Authors: Hui-Xuan Wu Tian-Yao Chu Junaid Iqbal Hong-Li Jiang Long Li Yan-Xuan Wu Hou-De Zhou Source Type: research

SGLT2 inhibitors: Effect on myocardial infarction and stroke in type 2 diabetes
J Clin Endocrinol Metab. 2023 Feb 28:dgad113. doi: 10.1210/clinem/dgad113. Online ahead of print.ABSTRACTBACKGROUND: SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3P MACE), predominantly by reducing cardiovascular death. However reduction of the individual components, myocardial infarction (MI) or stroke (fatal and non-fatal) events have not been well explored.METHODS: In this meta-analysis, we included data avail...
Source: The Journal of Clinical Endocrinology and Metabolism - March 1, 2023 Category: Endocrinology Authors: Pradip Mukhopadhyay Debmalya Sanyal Purushottam Chatterjee Kaushik Pandit Sujoy Ghosh Source Type: research

Insulin-like Growth Factor 1 and Risk of Cardiovascular Disease: Results from the UK Biobank Cohort Study
CONCLUSION: This study indicates that both low and high levels of circulating IGF-1 are associated with increased risk of CVD in general population. These results highlight the importance of monitoring IGF-1 status on cardiovascular health.PMID:36810801 | DOI:10.1210/clinem/dgad105
Source: The Journal of Clinical Endocrinology and Metabolism - February 22, 2023 Category: Endocrinology Authors: Jiayang Lin Linjie Yang Junlin Huang Yating Liu Xuzhen Lei Ruxin Chen Bingyan Xu Chensihan Huang Weijuan Dou Xueyun Wei Deying Liu Peizhen Zhang Yan Huang Zhimin Ma Huijie Zhang Source Type: research

Association of urinary nitrate with diabetes complication and disease-specific mortality among adults with hyperglycemia
CONCLUSIONS: Higher urinary nitrate is associated with lower risk of congestive heart failure and diabetic nephropathy, and lower risk of all-cause, CVD, and diabetes mortalities. These findings indicated that inorganic nitrate supplementation can be considered as a supplementary treatment for people with hyperglycemia.PMID:36576885 | DOI:10.1210/clinem/dgac741
Source: The Journal of Clinical Endocrinology and Metabolism - December 28, 2022 Category: Endocrinology Authors: Wenbo Jiang Jia Zhang Ruiming Yang Xinyi Sun Huanyu Wu Jiacheng Zhang Siyao Liu Changhao Sun Lifang Ma Tianshu Han Wei Wei Source Type: research

Pages: 1  2  3  4